Burmester et al. characterized the long-term safety profile of upadacitinib treatment across multiple rheumatic diseases.
A View from Abroad: The ACR Research Exchange Program
The most recent ACR/APLAR Research Exchange Program gave participants an opportunity to visit Singapore, learn from international research presentations and create connections with colleagues they may never otherwise have met.
Type I IFNs in Cutaneous Lupus & Dermatomyositis
Type I interferons (IFNs) play an important role in the immunopathogenesis of cutaneous lupus erythematosus and dermatomyositis skin inflammation, which could potentially be treated with IFN-targeted therapies.
Meet the Professor: Axial Spondyloarthritis
Axial spondyloarthritis (axSpA) is a complex, immune-mediated inflammatory disorder characterized by inflammatory back pain and axial arthritis. Typical of other diseases in the spondyloarthritis family, the clinical phenotypes can be diverse, and an array of comorbidities often accompanies the spinal disease. “In this Meet the Professor Session at ACR Convergence 2024,” says Christopher Ritchlin, MD,…
Lupus Update: Findings from the Latest Phase 3 Clinical Trials
Two new treatment studies among patients with systemic lupus erythematosus and lupus nephritis had promising results.
Cardiovascular & Cancer Risk Factors with JAK Inhibitors
In this study, researchers set out to determine the prevalence of baseline risk factors for cardiovascular outcomes and cancer among commercially insured patients with rheumatoid arthritis during their first dispensed treatment.
Is Intestinal Dysbiosis Associated with RA?
This study affirms that dysbiosis is a feature of rheumatoid arthritis (RA) and suggests that specific therapies may differentially modulate the gastrointestinal microbiota in RA.
What the Joints Say: Challenges of Tender & Swollen Joint Count Differences
In a new study published in ACR Open Rheumatology, researchers evaluated the impact of tender-swollen joint difference on functional outcomes in early RA and whether associations vary by joint size.
Interventions to Delay RA Onset
Two new successful trials in abatacept, APIPPRA and ARIAA, are the first to convincingly demonstrate the potential of a preventive approach to RA treatment.
Insight into the ACR’s Commitment to an Inclusive Committee Composition
“While our group carefully considered your application, I regret to inform you that you were not selected this year to serve as a committee volunteer.” When the email arrived, gently delivering the news that my application to volunteer with the ACR on a committee had not been accepted, my initial reaction was to dismiss it…
- « Previous Page
- 1
- …
- 14
- 15
- 16
- 17
- 18
- …
- 808
- Next Page »